Revenues (Tables)
|
9 Months Ended |
Sep. 30, 2020 |
|---|
| Revenues |
|
| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
|
September 30, |
|
September 30, |
|
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
Product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross product sales |
|
$ |
20,318 |
|
$ |
14,348 |
|
$ |
54,042 |
|
$ |
36,745 |
|
Discounts and allowances |
|
|
(4,029) |
|
|
(2,632) |
|
|
(10,099) |
|
|
(6,802) |
|
Product sales, net |
|
$ |
16,289 |
|
$ |
11,716 |
|
$ |
43,943 |
|
$ |
29,943 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues from collaborations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
License revenues |
|
|
2,100 |
|
|
7,750 |
|
|
41,958 |
|
|
12,249 |
|
Research and development services and others |
|
|
— |
|
|
1,391 |
|
|
4,270 |
|
|
1,696 |
|
Total revenues from collaborations |
|
|
2,100 |
|
|
9,141 |
|
|
46,228 |
|
|
13,945 |
|
Total revenues |
|
$ |
18,389 |
|
$ |
20,857 |
|
$ |
90,171 |
|
$ |
43,888 |
|
|
| Schedule of revenues from product sales disaggregated by customers |
The following table summarizes revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of our total revenues (as a percentage of total revenues):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
|
September 30, |
|
September 30, |
|
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
ASD Healthcare and Oncology Supply |
|
|
48% |
|
|
28% |
|
|
26% |
|
|
34% |
|
McKesson Specialty Care Distribution Corporation |
|
|
34% |
|
|
22% |
|
|
20% |
|
|
27% |
|
Daiichi |
|
|
11% |
|
|
— |
|
|
* |
|
|
— |
|
Aclaris |
|
|
— |
|
|
19% |
|
|
— |
|
|
* |
|
Celgene |
|
|
— |
|
|
18% |
|
|
— |
|
|
* |
|
Grifols |
|
|
— |
|
|
* |
|
|
49% |
|
|
11% |
|
|
| Schedule of product revenue allowance and reserve categories |
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2020 and 2019 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance at January 1, 2020 |
|
$ |
1,293 |
|
$ |
1,801 |
|
$ |
238 |
|
$ |
3,332 |
Provision related to current period sales |
|
|
5,625 |
|
|
2,775 |
|
|
676 |
|
|
9,076 |
Adjustment related to prior period sales |
|
|
(75) |
|
|
(490) |
|
|
565 |
|
|
— |
Credit or payments made during the period |
|
|
(5,020) |
|
|
(2,407) |
|
|
(72) |
|
|
(7,499) |
Balance at September 30, 2020 |
|
$ |
1,823 |
|
$ |
1,679 |
|
$ |
1,407 |
|
$ |
4,909 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance at January 1, 2019 |
|
$ |
622 |
|
$ |
843 |
|
$ |
170 |
|
$ |
1,635 |
Provision related to current period sales |
|
|
3,561 |
|
|
2,296 |
|
|
99 |
|
|
5,956 |
Credit or payments made during the period |
|
|
(2,932) |
|
|
(1,298) |
|
|
— |
|
|
(4,230) |
Balance at September 30, 2019 |
|
$ |
1,251 |
|
$ |
1,841 |
|
$ |
269 |
|
$ |
3,361 |
|